Market open
Oric Pharmaceuticals/$ORIC
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Oric Pharmaceuticals
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533. The Company has as one operating segment, focused on the discovery and development of therapies designed to counter the resistance mechanisms in cancer.
Ticker
$ORIC
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
122
ISIN
US68622P1093
Website
ORIC Metrics
BasicAdvanced
$346M
-
-$1.88
1.36
-
Price and volume
Market cap
$346M
Beta
1.36
52-week high
$14.67
52-week low
$3.90
Average daily volume
701K
Financial strength
Current ratio
12.002
Quick ratio
11.564
Long term debt to equity
2.504
Total debt to equity
3.967
Management effectiveness
Return on assets (TTM)
-30.87%
Return on equity (TTM)
-48.45%
Valuation
Price to book
1.57
Price to tangible book (TTM)
1.57
Price to free cash flow (TTM)
-2.954
Growth
Earnings per share change (TTM)
5.36%
3-year earnings per share growth (CAGR)
-5.23%
What the Analysts think about ORIC
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Oric Pharmaceuticals stock.
ORIC Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
ORIC Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
ORIC News
AllArticlesVideos
ORIC® Pharmaceuticals Reports First Quarter 2025 Financial Results and Operational Updates
GlobeNewsWire·1 week ago
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
GlobeNewsWire·2 weeks ago
ORIC® Pharmaceuticals Presents Preclinical Data to Support the Potential of ORIC-944 as a Best-in-Class PRC2 Inhibitor for the Treatment of Prostate Cancer at the 2025 American Association for Cancer Research (AACR) Annual Meeting
GlobeNewsWire·2 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Oric Pharmaceuticals stock?
Oric Pharmaceuticals (ORIC) has a market cap of $346M as of May 15, 2025.
What is the P/E ratio for Oric Pharmaceuticals stock?
The price to earnings (P/E) ratio for Oric Pharmaceuticals (ORIC) stock is 0 as of May 15, 2025.
Does Oric Pharmaceuticals stock pay dividends?
No, Oric Pharmaceuticals (ORIC) stock does not pay dividends to its shareholders as of May 15, 2025.
When is the next Oric Pharmaceuticals dividend payment date?
Oric Pharmaceuticals (ORIC) stock does not pay dividends to its shareholders.
What is the beta indicator for Oric Pharmaceuticals?
Oric Pharmaceuticals (ORIC) has a beta rating of 1.36. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.